Piper Sandler Maintains Overweight on Pacira BioSciences, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $50 to $42.
November 03, 2023 | 9:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Pacira BioSciences but lowered the price target from $50 to $42.
The news is directly about Pacira BioSciences. Piper Sandler's decision to maintain an Overweight rating indicates a positive outlook for the company. However, the lowering of the price target may create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100